Efficacy and safety of CM310 in severe eosinophilic chronic rhinosinusitis with nasal polyps (CROWNS-1): a multicentre, randomised, double-blind, placebo-controlled phase 2 clinical trial

BACKGROUND: Severe eosinophilic chronic rhinosinusitis with nasal polyps (ECRSwNP) remains the most relapsed subtype of uncontrolled CRSwNP. CM310, a humanised anti-interleukin (IL)-4 receptor alpha monoclonal antibody, inhibits IL-4 and IL-13 signaling which underlying eosinophilic inflammation. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yuan, Yan, Bing, Shen, Shen, Song, Xicheng, Jiang, Yan, Shi, Li, Zhao, Changqing, Yang, Yi, Jiang, Luyun, Li, Jiping, Ye, Jing, Liu, Jinfeng, Wan, Lijia, Yang, Yucheng, Chen, Jianjun, Liu, Feng, Su, Lizhong, Xu, Yu, Tan, Guolin, Yu, Shaoqing, Zhang, Yu, Wang, Lin, Liu, Shengyang, Yan, Hongyue, Liu, Wei, Chen, Bo, Wang, Chengshuo, Zhang, Luo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10359732/
https://www.ncbi.nlm.nih.gov/pubmed/37483544
http://dx.doi.org/10.1016/j.eclinm.2023.102076

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10359732/
https://www.ncbi.nlm.nih.gov/pubmed/37483544
http://dx.doi.org/10.1016/j.eclinm.2023.102076

Ejemplares similares